Based on the Biogaia AB ADR stock forecast from 0 analysts, the average analyst target price for Biogaia AB ADR is not available over the next 12 months. Biogaia AB ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biogaia AB ADR is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Biogaia AB ADR’s stock price was USD 12.09. Biogaia AB ADR’s stock price has changed by +0.00% over the past week, +8.82% over the past month and +44.27% over the last year.
No recent analyst target price found for Biogaia AB ADR
No recent average analyst rating found for Biogaia AB ADR
Company Overview Biogaia AB ADR
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori–the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden. Read Less
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures t...Read More
N/A
N/A
144
N/A
USD
USA
Adjusted Closing Price for Biogaia AB ADR (BIOGY)
Loading...
Unadjusted Closing Price for Biogaia AB ADR (BIOGY)
Frequently Asked Questions About Biogaia AB ADR (BIOGY) Stock
Stock Target Advisor's fundamental analysis for Biogaia AB ADR's stock is Slightly Bullish .
BIOGY stock's dividend yield is 0.88%.
Our analysis grades BIOGY stock's dividend yield at F. This means that BIOGY stock's dividend yield is above 7% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this BIOGY may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on BIOGY's stock to indicate what its average analyst target is.
BIOGY stock's Price/Earning ratio is 36.20.
Our analysis grades BIOGY stock's Price / Earning ratio at F. This means that BIOGY stock's Price/Earning ratio is above 80% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this BIOGY may be a overvalued for its sector.
The last closing price of BIOGY's stock was USD 12.09.
The most recent market capitalization for BIOGY is USD 0.80B.
Unfortunately we do not have enough analyst data on BIOGY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biogaia AB ADR's stock.
As per our most recent records Biogaia AB ADR has 144 Employees.
Sorry we do not have any infomation available on Biogaia AB ADR's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIOGY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
